IFN-α receptor mRNA expression in a united states sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy

Our aim was to assess whether, in the United states, with the predominant hepatitis C viral (HCV) genotypes 1a/I and 1b/II, hepatic interferon-α receptor (IFNAR) mRNA expression correlated with response to IFN therapy, levels of HCV RNA, or histologic activity index (HAI). Nine of 24 patients (38%) had an initial response to IFN treatment, 5 of whom (21%) had a sustained response. The corrected hepatic IFNAR mRNA expression (measured by RT-PCR) for the sustained responder group (mean ± SE, 0.16 ± 0.06, n = 5) was significantly higher than for the nonresponding group (0.059 ± 0.01, n = 15) (p < 0.02). Patients who relapsed had an intermediate value (0.092 ± 0.029, n = 4). Higher IFNAR expression was inversely correlated with a lower serum HCV RNA titer (p < 0.01), and responders to IFN treatment tended to have a lower titer of HCV RNA (p = 0.056). We found no significant correlation between the amounts of IFNAR with (1) the total HAI (low HAI ≤ 7, IFNAR 0.076 ± 0.013, n = 10; high HAI ≥ 8, IFNAR 0.092 ± 0.027, n = 14, ns) or (2) individual inflammation, necrosis, or fibrosis components of the HAI. As with Japanese HCV patients with genotypes 1b/II-2b/IV, higher hepatic IFNAR mRNA expression in the United States with predominant genotypes 1a/I and 1b/II appears to correlate with response to IFN therapy and a low HCV RNA titer but not with the total HAI or its components.